Skip to main content
. 2011 Jun 12;143(3):301–306. doi: 10.1016/j.vetimm.2011.06.008

Table 1.

Changes in the clinical score (CS) and analytical parameters between V1 (immediately before treatment) and V2 (two weeks after treatment).

Code Virus CS-V1 CS-V2 Erythrogram
Leukogram
Electroph.

Viral parameters
PCV Hgb RBC Leuko Ntr Lymp γ–s A/G CD4/CD8 p27 RT qPCR
C-1 FeLV 8 3 n–n n–n n–n n–n n–n n–n ↑–↑
(U)
↓–↓
(U)
n–nd
(F)

(F)
=
(U)
C-3 FeLV 7 4 n–n n–n n–n n–n n–n n–n ↑–n
(F)
↓–n
(F)
↓–↓
(U)

(U)

(U)

(U)
C-4 FeLV 5 0 ↓–n
(F)
↓–n
(F)
↓–n
(F)
n–n n–n ↓–n
(F)
↑–↑
(U)
↓–↓
(U)
n–n
(F)

(F)
=
(U)
C-6 FIV 9 5 n–n n–n n–n n–n n–n n–↓
(U)
↑–n
(F)
n–n nd–nd Neg. Neg. =
(U)
C-7 FIV 2 2 n–n n–n n–n n–n n–n n–n ↑–↑
(U)
↓–↓
(U)
↓–n
(F)
Neg. Neg.
(F)
C-8 FIV 8 1 n–n n–n n–n n–n n–n n–n ↑–n
(F)
n–n ↓–↓
(U)
Neg. Neg. =
(U)
C-9 FIV 0 0 n–n n–n n–n ↓–n
(F)
↓–n
(F)
n–n ↑–↑
(U)
n–↓
(U)
↓–n
(F)
Neg. Neg. =
(U)
C-10 FIV 0 0 n–n n–n n–n n–n n–n n–n ↑–n
(F)
n–n n–n Neg. Neg.
(U)
C-11 FIV 0 0 n–n n–n n–n n–n n–n n–↑
(U)
↑–n
(F)
↓–n
(F)
n–↓
(U)
Neg. Neg. =
(U)
C-12 FIV 7 2 n–n n–n ↓–n
(F)
n–n ↓–n
(F)
n–n ↑–↑
(U)
n–n n–n Neg. Neg. =
(U)

The CS was rated as described previously (Collado et al., submitted for publication). For the erythrogram, leukogram, electrophoretogram, and CD4/CD8 ratio the situation in V1 and V2 are provided as follows: n, within normal limits; ↓, below normal limits; ↑, above normal limits. For the viral parameters the change from V1 to V2 is provided as follows: ↓, ≥20% decrease; ↑, ≥20% increase; =, stable. (F), favorable change; (U) unfavorable change. PCV, packed cell volume; Hgb, hemoglobin concentration; RBC, erythrocyte counts; Leuko, leukocyte counts; Ntr, neutrophil counts; Lymph, lymphocyte counts; Electroph., electrophoretogram; γ–s, gammaglobulin concentration; nd, not determined; Neg., below the detection limit of the kit.